Post-licensing safety of fosamprenavir in HIV-infected children in Europe†

PURPOSE: Fosamprenavir, combined with low-dose ritonavir (FPV/r), is indicated for treatment of HIV-infected children aged ≥6 years in Europe. Our purpose was to assess the safety of licensed use of FPV/r in HIV-infected children reported to six cohorts in the European Pregnancy and Paediatric HIV C...

Descripción completa

Detalles Bibliográficos
Autores principales: Judd, Ali, Duong, Trinh, Galli, Luisa, Goetghebuer, Tessa, Ene, Luminita, Julian, Antoni Noguera, Amador, Jose Tomas Ramos, Pimenta, Jeanne Marie, Thorne, Claire, Giaquinto, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265189/
https://www.ncbi.nlm.nih.gov/pubmed/24741696
http://dx.doi.org/10.1002/pds.3543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265189/
https://www.ncbi.nlm.nih.gov/pubmed/24741696
http://dx.doi.org/10.1002/pds.3543

Ejemplares similares